1. Elizabeth Gardiner, TB Alliance Introducing New Tools & Approaches (INAT) - Berlin November 12, 2010

2. New Drug Working Group Co-Chairs: Mel Spigelman & Bill Bishai Members: 140+ including pharmaceutical companies, TB Alliance, TAG, Community Representative (Zimbabwe), BMGF Subgroups on Clinical Trial Capacity, Biology Targets, New Candidates, Knowledge & Tools Focus: R&D information sharing Website with pipeline, blog, videos Future: introduction of new drugs

3. Linkage with INAT For WGND Information about INAT Link to INAT website, slides about what INAT is Guidance Who/where is the TB drug market What patients/countries want How can products be used What dose works for uptake Help Community Representative deliver the right message to the audience For INAT Useful pipeline for INAT Go-to for scientific information on new drugs Other?

4. MDR Working Group Chair: Ahmer Khan, Indus Hospital Members: PIH, WHO/SEARO, WHO/GVA, Community Representatives (Nigeria & India), Union, BMGF, Resist-TB, USAID, Eli Lily, PATH Subgroups on Research, Infection Control & Prevention, Drug Management, Diagnostics Overseeing & providing guidance on MDR issues including subgroup topics, GLI, compassionate use, etc.

5. Role for INAT Should be grounded in framework of RTF Need for coordination more than encouragement Wants INAT to track/disseminate info on all related new tools activities across Partnership, Department, & TDR, donor-funded activities (e.g. STREAM study, LPA studies, GenExpert availability) identify sources of information on X, Y & Z (e.g. diagnostics, Resist-TB, TMC 207) Advocate for new tools but through existing structures